New Gel's drug interactions revealed in healthy volunteer study
NCT ID NCT06930872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a gel called ZYN002 affects the way the body processes other drugs. Twenty-nine healthy adults took ZYN002 along with several common medications to see if there were any changes in drug levels. The goal was to understand potential interactions so doctors can prescribe ZYN002 more safely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
29 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female adults, 18-55 years of age, inclusive, at the time of Screening. 2. Judged by the Investigator to be in generally good health at Screening based upon the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range, but acceptable, must be documented as not clinically significant (NCS) at the discretion of the Investigator. 3. Participants must have a body mass index between 18 and 30 kg/m² at the time of Screening. 4. Females of childbearing potential must have a negative pregnancy test result at the Screening Visit and on Day -1 before admission to the CRU. Females who are not of childbearing potential are defined as being postmenopausal for \>=12 months or having a history of hysterectomy and/or bilateral oophorectomy and/or bilateral tubal ligation. Exclusion Criteria: 1. A) Females who are pregnant, nursing or planning to become pregnant or females of childbearing potential, who are unwilling to use medically acceptable method of contraception or B) Males with a female partner who is pregnant, nursing, or planning to become pregnant or a female partner of childbearing potential who is unwilling to use a medically acceptable method of contraception. 2. Are homozygous for CYP2C19\*2 or heterozygous carriers of CYP2C19\*2/CYP2C19\*3 or CYP2C9\*2/CYP2C9\*3 or CYP2D6\*2/CYP2D6\*3 haplotypes categorized as poor metabolizers. 3. Has consumed alcohol 48 hours prior to Day 1 or during the study. 4. Has eaten any food or drink/beverage containing, grapefruit or grapefruit juice, apple, cranberry, Seville orange or orange juice, vegetables from the mustard family (e.g., kale, spinach, broccoli, watercress, collard greens, kohlrabi, brussels sprouts, parsley, mustard greens, endive, red cabbage, asparagus, or mustard), and chargrilled meats within one week prior to study start (Day -1).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug interaction are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pfizer tests experimental drug to slow stomach emptying in obesity
- Study reveals hidden risks of mixing Beta-Blockers and Anti-Inflammatories
- New computer tool aims to catch dangerous drug mixes in older patients
- Gene study aims to predict chemo side effects in kids with leukemia
- New study aims to predict dangerous side effects of common breast cancer drugs
- 12 healthy volunteers test drug combo in Early-Stage study